Aurinia Pharmaceuticals Inc. (AUPH) — closed signal from October 31, 2025
Target reached Published before the outcome was known, scored automatically when the window closed on January 29, 2026.
Predicted vs. what happened
What happened
Reached its target in 4 days.
The thesis — published October 31, 2025
Aurinia looks balanced: investor interest is healthy and the business story is solid. The share price recently moved above the typical 12-month analyst target, a sign investors may be rethinking value. Buying has picked up and the recent average price is climbing. If markets stay friendly and Lupkynis sales remain steady, interest should continue. Biotech swings are common.
Primary drivers
- Lupkynis sales are growing and the drug is gaining traction with prescribers
- More buyers than usual and a rising recent average price show firm demand
- Price moved above the typical analyst target, hinting at a fresh re-rating
- Positive mood and steady results create a balanced, practical setup
How it played out
AUPH: target reached in 4 days
Lyra published AUPH at $12.33 on 2025-10-31, with a short-term window through 2026-01-29. The thesis expected 22% growth. It pointed to growing Lupkynis sales, stronger buyer interest, a rising recent average price, and a move above the typical analyst target as signs that investors may have been rethinking value.
The price reached the target in 4 days. It kept rising after that and peaked at $16.54 on 2025-12-23, a 34.1% gain. By the end of the window, AUPH was at $14.65. The thesis played out.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.